title: [A case of papillary renal cell carcinoma type 2 resistant to sunitinib responded to second line therapy with axitinib].
abstract: According to previous studies, papillary renal cell carcinoma (pRCC) type 2 is known to have a poor prognosis, especially in cases with metastases. We report a case of pRCC that responded well to axitinib administered as second line therapy. The patient was a 52-year-old woman who presented at our hospital with an incidental tumor on the left kidney. She underwent laparoscopic radical nephrectomy, and the pathological diagnosis was pRCC type 2, grade 3 pT1b. Multiple lung and bone metastases were observed following the four months, and histological findings of lung metastases was metastatic RCC. Although sunitinib was administered as first line therapy, tumor progression was observed after the first cycle of treatment. Therefore, axitinib (10 mg/day) was administrated as second-line therapy and was gradually increased to 14 mg/day. Five months after the administration of axitinib, the maximum tumor diameter of the lung metastases reduced by 83%. At present, eight months have passed since the start of axtinib administration, but the response was still maintained and the adverse events were generally tolerable.
authors.forename: Gen
authors.initials: G
authors.lastname: Ishii
authors.forename: Takashi
authors.initials: T
authors.lastname: Hatano
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Endo
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Seki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yamada
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kimura
authors.forename: Shin
authors.initials: S
authors.lastname: Egawa
mesh_terms: D000077784:Axitinib; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007191:Indazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib